Related Experiment Video
Updated: Mar 8, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.6K
Exacerbation of Psoriasis by Ibuprofen
Indian Journal of Dermatology, Venereology and Leprology
|February 2, 2017
Summary
Ibuprofen therapy can worsen psoriatic arthritis skin lesions in middle-aged women. This case highlights potential adverse reactions to nonsteroidal anti-inflammatory drugs in autoimmune skin conditions.
Area of Science:
- Dermatology
- Rheumatology
- Pharmacology
Background:
- Psoriatic arthritis is a chronic inflammatory condition affecting joints and skin.
- Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are commonly used for symptom management.
- NSAIDs can have various side effects, necessitating careful patient monitoring.
Observation:
- A middle-aged female patient with psoriatic arthritis experienced worsening of skin lesions during ibuprofen therapy.
- The exacerbation of skin lesions was directly linked to the initiation of ibuprofen treatment.
Findings:
- Ibuprofen therapy was associated with an exacerbation of psoriatic skin lesions.
- The exact mechanisms for this adverse reaction require further investigation but may involve inflammatory pathways.
Implications:
- Clinicians should consider the potential for NSAIDs to exacerbate psoriatic skin lesions.
- Alternative pain management strategies may be necessary for patients with psoriatic arthritis and significant skin involvement.
- Further research is warranted to elucidate the mechanisms underlying NSAID-induced skin lesion exacerbation in psoriatic arthritis.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
618
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
618
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
588
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
588
01:29Drugs for Treatment of Ulcerative Colitis in IBD
579
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
579
01:29Inflammatory Bowel Disease IV: Pharmacological Management
875
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
875
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
672
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
672
01:17Irritable Bowel Syndrome I: Introduction
1.3K
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
1.3K